Cargando…

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

The NEAT trial reported considerable benefit for ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil) of 28% for relapse-free survival (RFS) and 30% for overall survival (OS), when compared with classical CMF in early breast cancer. To assess tolerability, toxicity, dose i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Earl, H M, Hiller, L, Dunn, J A, Bathers, S, Harvey, P, Stanley, A, Grieve, R J, Agrawal, R K, Fernando, I N, Brunt, A M, McAdam, K, O'Reilly, S, Rea, D W, Spooner, D, Poole, C J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570521/ https://www.ncbi.nlm.nih.gov/pubmed/18797468 http://dx.doi.org/10.1038/sj.bjc.6604674

Ejemplares similares

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)

tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation
por: Wardley, A M, et al.
Publicado: (2008)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
por: Twelves, C. J., et al.
Publicado: (1989)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial
por: Fernando, Indrajit N., et al.
Publicado: (2020)

Neatness
Publicado: (1872)

The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
por: Lind, M. J., et al.
Publicado: (1995)

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
por: Twelves, C. J., et al.
Publicado: (1992)

Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumor-bearing mice
por: Wang, Limei, et al.
Publicado: (2019)

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
por: Pacilio, C, et al.
Publicado: (2006)

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
por: Jones, R. D., et al.
Publicado: (1990)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation
por: Leong, T, et al.
Publicado: (2003)

Weekly epirubicin in patients with hormone-resistant prostate cancer
por: Petrioli, R, et al.
Publicado: (2002)

Functional dissection of NEAT1 using genome editing reveals substantial localization of the NEAT1_1 isoform outside paraspeckles
por: Li, Ruohan, et al.
Publicado: (2017)

What is the effect of adjusting epirubicin doses for body surface area?
por: Dobbs, N. A., et al.
Publicado: (1998)

Epirubicin-induced Kounis syndrome
por: Liang, Hui-zhu, et al.
Publicado: (2021)

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
por: Topham, C., et al.
Publicado: (1991)

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
por: JÃ¤rvinen, T. A., et al.
Publicado: (1998)

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial
por: Waters, J S, et al.
Publicado: (1999)

Neatness in Dress at Home
Publicado: (1891)

Neatness in Dress at Home
Publicado: (1890)

A prolific catalyst for dehydrogenation of neat formic acid
por: Celaje, Jeff Joseph A., et al.
Publicado: (2016)

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
por: Schenone, Aaron D, et al.
Publicado: (2014)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
por: Baldini, E, et al.
Publicado: (2004)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

The NEAT Domain-Containing Proteins of Clostridium perfringens Bind Heme
por: Choo, Jocelyn M., et al.
Publicado: (2016)

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
por: Cameron, David, et al.
Publicado: (2017)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
por: Eickhoff, A, et al.
Publicado: (2006)

Neat Way of Giving Quinine
Publicado: (1890)

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
por: Gennari, A, et al.
Publicado: (2004)

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000)

Vitamin C-driven epirubicin loading into liposomes
por: Lipka, Dominik, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gd3krvrpicsl00nhi9v4g901ev